Bisphosphonate Marketers Push Dosing Advantages After Feb. 6 Fosamax Patent Expiry
This article was originally published in The Pink Sheet Daily
Executive Summary
Branded osteoporosis drug makers gird for a hit from launch of a low-cost version of Merck’s market leading alendronate.
You may also be interested in...
NICE Throws P&G/Sanofi A Bone With Osteoporosis Guidance
Reversing an earlier appraisal, UK agency recommends Actonel as alternative to generic Fosamax in prevention of fracture in postmenopausal osteoporosis.
NICE Throws P&G/Sanofi A Bone With Osteoporosis Guidance
Reversing an earlier appraisal, UK agency recommends Actonel as alternative to generic Fosamax in prevention of fracture in postmenopausal osteoporosis.
Tamiflu Drags On Roche’s First Quarter Sales
Sales of Rituxan, Herceptin, Avastin and Boniva increase by double digits.